A new study shows, for the first time, how the human genome folds and moves in 3D over time to control when genes turn on and ...

New 3D genome maps reveal how DNA folding controls gene activity, offering fresh clues into disease and cell function.

One of the most detailed 3D maps of how the human chromosomes are organized and folded within a cell's nucleus is published ...

AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study ...

CAAR ruled that multi-functional PCR instruments cannot be treated as spectrometers where optical detection is only one part ...

Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted ...

This thesis aimed to expand understanding of CPSs through identification of novel childhood cancer predisposition genes and improved insights into known ones. Detailed germline and tumor analyses were ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2025 Earnings Call Transcript November 13, 2025 Bionano Genomics, Inc. beats earnings expectations. Reported EPS is $-1.59292, expectations were $-1.81.

Bionano Genomics, Inc. beats earnings expectations. Reported EPS is $-1.59292, expectations were $-1.81. Operator: Good day, and welcome to the Bionano Third Quarter 2025 Earnings Conference Call.

Pregnancy loss may occur in as many as 25% of all pregnancies. Most of these losses occur in the first trimester, and about half are caused by genetic or chromosomal issues. When pregnancy loss occurs ...

Total Revenue-- $7.4 million in 2025, a 21% increase over 2024, with core revenue up 12% after adjusting for a $500,000 write-down in discontinued clinical services in 2024. Flow Cells Sold-- 8,390 ...